Objectives Increasing evidence suggests that inflammation is involved in Alzheimer's
disease (AD) pathology. This study quantitatively summarised the data on peripheral …

Due to the ability of the blood–brain barrier (BBB) to prevent the entry of drugs into the brain,
it is a challenge to treat central nervous system disorders pharmacologically. The …

Medical diagnosis and therapy are essential for providing patients with proper care,
although inefficient diagnosis and therapy are usually associated with either improper …

Currently, Alzheimer's disease (AD) accounts for more than half of all dementia cases.
Although genetics, age, and environmental factors affect the disease, the cause of AD is not …

Neuropsychiatric diseases are one of the main causes of disability, affecting millions of
people. Various drugs are used for its treatment, although no effective therapy has been …

Chitosan, a biocompatible natural polysaccharide is frequently reported carrier material in
targeted drug delivery to treat neurodegenerative disorders. Chitosan and its biodegradable …

The present paper focuses on the development and in vitro/in vivo characterization of
nanoparticles composed of poly-(D, L)-Lactide-co-Glycolide (PLGA) loading Bacoside-A, as …

The blood-brain barrier (BBB) is a sophisticated and very selective dynamic interface
composed of endothelial cells expressing enzymes, transport systems, and receptors that …

The discipline of neurotheranostics was forged to improve diagnostic and therapeutic
clinical outcomes for neurological disorders. Research was facilitated, in largest measure …

Background Increasing evidence implicates oxidative stress (OS) in Alzheimer disease (AD)
and mild cognitive impairment (MCI). Depletion of the brain antioxidant glutathione (GSH) …